AVITA Medical INC. (ASX: AVH): Technical Rally Driven by Solid Fundamentals
AVITA Medical is strengthening its commercial position as revenue growth improves, cash burn reduces, and its regenerative medicine portfolio expands. The company’s progress in product adoption and operational efficiency keeps it positioned as a speculative healthcare growth story.
OncoSil Medical (ASX: OSL): FDA Approval Lands and Commercial Execution Takes Centre Stage
OncoSil Medical is moving into commercial execution after US FDA approval, growing adoption in Spain, fresh institutional funding, and manufacturing progress, with investors watching reimbursement, hospital uptake, and demand.
Racura Oncology (ASX: RAC): CEO Keeps Buying near 52-Week Lows as MYC Cancer Drug Advances
Racura Oncology's CEO-owned Nucleics added 23,000 shares near a 52-week low, while new data backs the company's MYC-silencing cancer drug ahead of a November Singapore conference.
Telstra Group (ASX: TLS) - A Defensive Cash Compounder with Embedded Digital Optionality
We view Telstra as a highly resilient, structurally advantaged cash-generating business within the Australian equity market, offering strong earnings quality and downside protection despite limited headline growth. Its focus on network leadership, disciplined capital management and monetisation of digital and infrastructure assets supports stable free cash flow and reliable capital returns, particularly in a softer macro environment. We believe the market continues to undervalue Telstra’s leverage to long-term data demand, the durability of its mobile economics, and the embedded optionality in InfraCo and enterprise digital services.
Why is SportsHero's (ASX: SHO) share price rising and how much higher can it go?
SportsHero (ASX: SHO) is an early-stage Australian sports gamification and media company focused on mobile-first prediction and gaming platforms across Southeast Asia, primarily Indonesia. It offers leveraged exposure to regional digital gaming growth but carries high execution, funding and profitability risk typical of small-cap platform build-outs.
PlaySide Studios (ASX: PLY) Strategic Pivot: Where can its share price go after the recent volatility?
PlaySide Studios is shifting from contract development to original IP and publishing to boost margins and growth. Strong partnerships and a solid pipeline support optimism, but revenue volatility and past unprofitability keep investor sentiment cautious.